Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

20 avr. 2015 13h30 HE | Source: NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals to Present New Data on NGM282 at the European Association for the Study of the Liver International Liver Congress(TM) 2015

SOUTH SAN FRANCISCO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc., a privately held biotechnology company that seeks to translate powerful biology into transformative...
24 mars 2015 09h00 HE | Source: NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals Announces Positive Phase 2 Clinical Data in Primary Biliary Cirrhosis Patients for NGM282, a First-in-Class Investigational Medicine

Data demonstrate statistically significant, dose-dependent and clinically meaningful reductions in disease activity Results support NGM282 as a potential treatment for a variety of orphan...
02 mars 2015 09h00 HE | Source: NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals Announces Expansion of Management Team

SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that Jeff Jonker has been named President and...